Recent

% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • terry_amln terry_amln Apr 27, 2014 8:06 AM Flag

    Expanded Reimbursement in Canada

     

    International Milestones
    Expanded Reimbursement in Canada and Inclusion in Leading German Physician Guidelines Increase Genomic Health's Impact in Key International Markets
    REDWOOD CITY, Calif., April 22, 2014 /PRNewswire/ -- Genomic Health, Inc. (GHDX) today announced two important international milestones including additional reimbursement in Canada and the inclusion of the Oncotype DX® breast cancer test in major German clinical guidelines. In Canada, the BC Cancer Agency in British Columbia agreed to fund the Oncotype DX breast cancer test for eligible patients, expanding reimbursement to more than 80 percent of the country's population. In Germany, updated guidelines from the AGO (Gynecologic Oncology Working Group) now recommend the Oncotype DX breast cancer test as the only gene expression test to predict chemotherapy benefit in early-stage hormone receptor-positive invasive breast cancer.
    "The opportunity to reach breast cancer patients worldwide is a key area of focus and investment for 2014 that will drive future growth," said Brad Cole, chief operating officer, Genomic Health. "These two accomplishments, combined with the National Institute for Health and Care Excellence's (NICE's) recent recommendation of Oncotype DX, represent significant progress internationally."

    This topic is deleted.
 
GHDX
26.95-0.53(-1.93%)Aug 23 4:00 PMEDT